platinum

Documents about platinum

• Dose-finding Study in Platinum-Resistant Ovarian Cancer#1163796ClinicalTrials.gov
• Weekly Paclitaxel With or Without Pazopanib in Platinum Resistant or Refractory Ovarian Cancer#1044191ClinicalTrials.gov
• Platinum Rechallenge in Patients With Platinum-sensitive mTNBC#811383ClinicalTrials.gov
• Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer#891801ClinicalTrials.gov
• Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer#1164116ClinicalTrials.gov
• Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian#839531ClinicalTrials.gov
• Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy#1394815ClinicalTrials.gov
• Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer#904991ClinicalTrials.gov
• Effect of Platinum-based Versus Non-platinum-based Neoadjuvant Chemotherapy in Triple-negative Breast Cancer#1150840ClinicalTrials.gov
• Chk2 Inhibitor for Recurrent EpitheliAl periToneal, fallopIan or oVarian cancEr (CREATIVE Phase IA Trial)#1484017ClinicalTrials.gov
• Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer#893627ClinicalTrials.gov
• A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer#993599ClinicalTrials.gov
• Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer#1442705ClinicalTrials.gov
• Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian Cancer#1438388ClinicalTrials.gov
• Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.#1085462ClinicalTrials.gov
• Olaparib Maintenance With Pembrolizumab & Bevacizumab in BRCA Non-mutated Patients With Platinum-sensitive Recurrent Ovarian Cancer#1072423ClinicalTrials.gov
• A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer#1499149ClinicalTrials.gov
• Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer#1243058ClinicalTrials.gov
• Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy#1431338ClinicalTrials.gov
• Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer#831976ClinicalTrials.gov
• A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200)#1196226ClinicalTrials.gov
• Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)#172300ClinicalTrials.gov
• PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer#1245106ClinicalTrials.gov
• MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer#826793ClinicalTrials.gov
• Abundance and distribution of platinum-group elements in orogenic lherzolites; a case study in a Fontete Rouge lherzolite (French Pyrenees)#251451Open Research
• Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer#1381702ClinicalTrials.gov
• Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer#888024ClinicalTrials.gov
• Study of XL999 in Patients With Previously Treated Ovarian Cancer#1073859ClinicalTrials.gov
• P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer#1007656ClinicalTrials.gov
• Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers#1060146ClinicalTrials.gov
• Rediscovery of the Elements: The Platinum Metals#681143UNT Digital Library
• Anticancer platinum (IV) prodrugs with novel modes of activity#685923ScholarBank@NUS
• FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer#909761ClinicalTrials.gov
• Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy#918549ClinicalTrials.gov
• A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers#1112790ClinicalTrials.gov
• Ultralow Platinum Content in Defect-Rich Tungsten Disulfide: Approaching Platinum Performance in Proton Exchange Membrane Water Electrolyzers.#150111NCBI PubMed Central
• Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer#887716ClinicalTrials.gov
• Efficacy of Plasmid Elenagen in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Cancer#1282409ClinicalTrials.gov
• Numerical experimental and computational data for platinum incorporation in thiolate-protected Au25 clusters#1478995Dane Badawcze UW Dataverse OAI Archive
• Anlotinib Combined With Niraparib Dual Therapy in Platinum-resistant Recurrent Ovarian Clear Cell Carcinoma.#1086991ClinicalTrials.gov
• Trial Of Cisplatin And KML-001 in Platinum Responsive Malignancies#1183769ClinicalTrials.gov
• OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC#201615ClinicalTrials.gov
• Statins Effect on Incidence of Side Effects of Platinum Based Chemotherapy#803853ClinicalTrials.gov
• BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients#912592ClinicalTrials.gov
• Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer#1293182ClinicalTrials.gov
• Data publication: Probing Neptunium-Platinum bonding in 2-pyridyloxy bridged heterobi- and trimetallic complexes#1405484RODARE
• Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer#905980ClinicalTrials.gov
• Toward Optimized Platinum Therapy: A Risk Prediction Model for Toxicity Based on Platinum Accumulation and Its Impact on Treatment Outcomes.#280917NCBI PubMed Central
• Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer#865964ClinicalTrials.gov
• Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer#981779ClinicalTrials.gov